Cancer Sci 107 (2016) 207--216

**Funding Information**

Japan Society for the Promotion of Science, (grant/award numbers: '22791569' and '24592589').

Targeted immunotherapy to promote anti‐tumor immune responses, such as cancer vaccination, has been examined against various types of cancer as an adjuvant for conventional cancer therapy.[1](#cas12866-bib-0001){ref-type="ref"} Despite the fact that cancer immunotherapy has been shown to induce significant immunological responses, the clinical response has been limited. Head and neck cancer is the sixth most common malignancy worldwide, with approximately 500 000 patients diagnosed annually.[2](#cas12866-bib-0002){ref-type="ref"} Despite advances in combination treatment modalities involving surgery, radiotherapy and chemotherapy for advanced head and neck squamous cell carcinoma (HNSCC), the survival rate remains low. The poor prognosis is thought to be linked to the fact that HNSCC strongly influences the host immune system.[3](#cas12866-bib-0003){ref-type="ref"} The anti‐tumor responses in HNSCC patients are compromised due to the presence of functional defects or increased T cell apoptosis, both circulating and tumor‐infiltrating;[4](#cas12866-bib-0004){ref-type="ref"} however, the mechanism underlying this depressed immune response is unclear. Tumors are thought to evoke many strategies to evade the host immune system, such as the induction of suppressive cells, including regulatory T cells and myeloid‐derived suppressor cells.

Myeloid‐derived suppressor cells (MDSC) are a heterogeneous population of immature and progenitor myeloid cells with immunosuppressive roles in infection,[5](#cas12866-bib-0005){ref-type="ref"} autoimmune disease[6](#cas12866-bib-0006){ref-type="ref"} and various types of cancer.[7](#cas12866-bib-0007){ref-type="ref"} MDSC have the potential to suppress the immune response by secreting mediators such as cytokines,[8](#cas12866-bib-0008){ref-type="ref"} reactive oxygen species (ROS) and nitric oxide (NO).[9](#cas12866-bib-0009){ref-type="ref"} It has been reported that an increased percentage of MDSC is associated with an increased risk of death in several types of cancer.[10](#cas12866-bib-0010){ref-type="ref"}, [11](#cas12866-bib-0011){ref-type="ref"} In humans, MDSC express the common myeloid markers CD11b and CD33, but lack the mature myeloid marker HLA‐DR, and a recent proposal subdivided them into two groups: CD15^+^ granulocytic MDSC (G‐MDSC) and CD14^+^ monocytic MDSC (M‐MDSC).[12](#cas12866-bib-0012){ref-type="ref"} However, the suppressive functions of MDSC subsets are still unclear in patients with cancer, including those with HNSCC.

Invariant NKT (iNKT) cells are a unique lymphocyte subpopulation characterized by the co‐expression of a T cell receptor and lineage markers of natural killer (NK) cells.[13](#cas12866-bib-0013){ref-type="ref"}, [14](#cas12866-bib-0014){ref-type="ref"}, [15](#cas12866-bib-0015){ref-type="ref"} Human iNKT cells express the invariant Vα24 antigen receptor and are activated by a glycolipid ligand, α‐galactosylceramide (αGalCer), in a CD1d‐dependent manner,[16](#cas12866-bib-0016){ref-type="ref"}, [17](#cas12866-bib-0017){ref-type="ref"}, [18](#cas12866-bib-0018){ref-type="ref"} and exhibit anti‐tumor activity against various cancers.[19](#cas12866-bib-0019){ref-type="ref"}, [20](#cas12866-bib-0020){ref-type="ref"}, [21](#cas12866-bib-0021){ref-type="ref"} Recently, the clinical efficacy of an iNKT cell‐based cancer immunotherapy has been demonstrated for head and neck cancer patients.[22](#cas12866-bib-0022){ref-type="ref"}, [23](#cas12866-bib-0023){ref-type="ref"}, [24](#cas12866-bib-0024){ref-type="ref"}, [25](#cas12866-bib-0025){ref-type="ref"} However, the effects of MDSC on iNKT cells in cancer patients have been unclear. In this study, we investigated the effect of circulating MDSC subsets on the peripheral immune response, especially on iNKT cells, and the association with clinical stage and prognosis in HNSCC patients.

Materials and Methods {#cas12866-sec-0002}
=====================

Study subjects {#cas12866-sec-0003}
--------------

The clinical characteristics of the study subjects are summarized in Table [1](#cas12866-tbl-0001){ref-type="table-wrap"}. The following patients were enrolled for the present study: 32 patients (34--83 years old) with HNSCC, nine patients (35--67 years old; one patient with stage I, one patient with stage III, seven patients with stage IV) with thyroid papillary carcinoma, seven patients (18--60 years old) with salivary gland pleomorphic adenoma and 18 healthy donors (35--63 years old). The study was approved by the institutional review board. Patients did not receive any treatment before sample collection. All HNSCC patients were enrolled in the study before receiving standard treatments, including surgery, radiotherapy and chemotherapy. Informed consent was obtained from all individual participants included in the study. All procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

###### 

The characteristics of head and neck tumor patients and healthy donors

  Sample                                  Total number   Median age (range)   Gender (male/female)
  --------------------------------------- -------------- -------------------- ----------------------
  Healthy donors                          18             47.5 (35--63)        9/9
  Pleomorphic adenoma                     7              43.9 (18--60)        1/6
  Thyroid papillary adenocarcinoma        9              56.3 (35--67)        2/7
  Head and neck squamous cell carcinoma   32             67.0 (34--83)        26/6

  Age   Gender   Primary of HNSCC   TNM        Stage
  ----- -------- ------------------ ---------- -------
  34    F        Tongue             T1N0M0     I
  67    M        Tongue             T1N0M0     I
  39    M        Tongue             T4aN2cM0   IV
  77    M        Tongue             T2N2bM0    IV
  64    M        Tongue             T2N2bM0    IV
  77    M        Tongue             T2N2bM0    IV
  64    F        Oral floor         T4N2M0     IV
  74    M        Larynx             T1aN0M0    I
  81    M        Larynx             T2N0M0     II
  75    M        Larynx             T2N1M0     III
  78    M        Larynx             T3N0M0     III
  72    M        Larynx             T3N0M0     III
  51    M        Larynx             T4aN2cM0   IV
  65    M        Maxillary sinus    T3N0M0     III
  60    M        Maxillary sinus    T4aN0M0    IV
  40    F        Maxillary sinus    T4aN0M0    IV
  71    M        Maxillary sinus    T4bN0M0    IV
  74    M        Maxillary sinus    T4bN2bM0   IV
  75    M        Maxillary sinus    T3N1M0     III
  56    M        Oropharynx         T1N2bM0    IV
  63    F        Oropharynx         T2N2bM0    IV
  77    M        Oropharynx         T2N2bM0    IV
  67    F        Oropharynx         T4N3M0     IV
  82    M        Oropharynx         T4N2M1     IV
  66    M        Hypopharynx        T1N0M0     I
  71    M        Hypopharynx        T2N1M0     III
  57    M        Hypopharynx        T1N3M0     IV
  68    M        Hypopharynx        T4aN2bM0   IV
  69    M        Hypopharynx        T4aN2cM1   IV
  74    F        Hypopharynx        T4aN0M0    IV
  75    M        Hypopharynx        T4N2cM0    IV
  83    M        Hypopharynx        T4bN2bM0   IV
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Blood samples {#cas12866-sec-0004}
-------------

Peripheral blood cells (PBC) were isolated from a heparinized venous blood sample by density gradient centrifugation within 2 h of sample collection. Blood was diluted 1:1 with saline before being layered onto Ficoll‐Paque PLUS (GE Healthcare Bio‐Sciences, Uppsala, Sweden). After centrifugation for 30 min at 600 `g`, PBC were collected from the plasma‐Ficoll interphase. The cells were immediately used for flow cytometry or were assayed.

Antibodies and flow cytometry {#cas12866-sec-0005}
-----------------------------

Granulocytic MDSC were characterized as HLA‐DR‐negative, lineage (CD3, CD14, CD19, CD56)‐negative and CD15‐positive (HLA‐DR^−^ Lin^−^ CD15^+^), while M‐MDSC were identified as CD14^+^ HLA‐DR^−/low^.[26](#cas12866-bib-0026){ref-type="ref"}, [27](#cas12866-bib-0027){ref-type="ref"}, [28](#cas12866-bib-0028){ref-type="ref"} Anti‐HLA‐DR, CD33, Vα24‐FITC, CD3, CD19, CD56, CD11b, Vβ11‐PE, CD14‐PerCP, CD3 and CD15‐APC (BD Biosciences, San Diego, CA, USA) antibodies were used to separate and analyze T cells, B cells, NK cells and iNKT cells. Propidium iodide solution (Sigma‐Aldrich, St. Louis, MO, USA) and AnnexinV (BD Biosciences) were used to identify dead cells. The phenotype of the cells was evaluated by multicolor flow cytometry using a FACS Calibur or FACS Canto (BD Biosciences). The data were analyzed with FlowJo software (Tree Star, Ashland, OR, USA).

T cell proliferation assay {#cas12866-sec-0006}
--------------------------

Peripheral blood cells were labeled with an anti‐CD15‐APC antibody and anti‐APC magnetic beads (Miltenyi Biotec K.K., Tokyo, Japan). The CD15^+^ cells were depleted from PBC using MiniMACS columns (Miltenyi Biotec). The control PBC were labeled with anti‐mouse IgG1‐APC antibody and anti‐APC magnet beads. In other experiments, the sorted CD15^+^ cells were added to the PBC at up to 10 times higher concentration than in original PBC. PBC with and without CD15^+^ cells were labeled with carboxy‐fluorescein diacetate succinimidyl ester (CFSE) (Cayman Chemichal, Ann Arbor, MI, USA) or CellTrace Violet (CTV) (Invitrogen, Carlsbad, CA, USA), and were stimulated with anti‐CD3 (5 μg/mL) (eBioscience, San Diego, CA, USA) and anti‐CD28 (5 μg/mL) (Miltenyi Biotec) antibodies in RPMI 1640 medium. In some experiments H~2~O~2~ scavenger catalase (100 U/mL, catalase from bovine liver; Sigma‐Aldrich) was added into the T cell culture. After a 48‐h or 72‐h incubation, the cells were collected and stained with anti‐CD3‐PE, CD4‐APC and CD8‐APC antibodies for flow cytometric analysis. The proliferation of CD4^+^ and CD8^+^ T cells was assessed by CFSE or CTV fluorescence intensity.

Cytokine assay {#cas12866-sec-0007}
--------------

Interleukin (IL)‐4, IL‐10 and GM‐CSF in the culture medium were measured with Bio‐Plex Pro (Bio‐Rad Laboratories, Hercules CA, USA) according to the manufacturer\'s protocol. Briefly, antibody coupled capture beads were prepared and plated. After washing, samples and standards were added in duplicate to the beads in the wells. The detection antibodies were added to each well. Streptavidin‐phycoerythin solution was added to the wells. The plate was read and analyzed with the Bio‐Plex system. The absolute concentrations of the samples were determined by construction of a standard curve for each analysis.

Invariant NKT cell proliferation and IFN‐γ ELISPOT assay {#cas12866-sec-0008}
--------------------------------------------------------

Peripheral blood cells were depleted of CD15^+^ cells, as previously described, and were cultured in RPMI 1640 medium in the presence of IL‐2 (100 JRU/mL; Shionogi, Osaka, Japan) and αGalCer (100 ng/mL) to expand the iNKT cells. After 5 days of culture, the cells were collected and stained for flow cytometry using anti‐Vα24‐FITC, Vβ11‐PE and CD3‐APC antibodies. For the IFN‐γ ELISPOT assay, the cultured iNKT cells in the presence or absence of CD15^+^ cells were adjusted to 5 × 10^5^ cells per well, and stimulated with αGalCer. The iNKT cell responses were evaluated by counting the number of spots for IFN‐γ production using an ImmunoScan computer system and ImmunoSpot software (CTL, Cleveland, OH, USA).

Statistical analyses {#cas12866-sec-0009}
--------------------

The statistical analyses of the means and correlations were evaluated with nonparametric (Mann--Whitney *U*‐test or Spearman\'s test) tests, the change of G‐MDSC before and after treatment with a nonparametric (Wilcoxon signed rank test) test, and the overall survival with a log‐rank test. All *P*‐values were two‐sided, and *P*‐values \<0.05 were considered to be statistically significant.

Results {#cas12866-sec-0010}
=======

Phenotypic characterization of myeloid‐derived suppressor cells subpopulations in peripheral blood {#cas12866-sec-0011}
--------------------------------------------------------------------------------------------------

Compared with healthy donors, a significant increase in CD14^+^ HLA‐DR^−/low^ M‐MDSC and HLA‐DR^−^ Lin^−^ CD15^+^ G‐MDSC was observed in HNSCC patients. No significant correlation was seen between the patient age and the ratio of M‐MDSC or G‐MDSC in HNSCC patients (data not shown). Representative staining profiles of M‐MDSC and G‐MDSC are shown (Fig. [1](#cas12866-fig-0001){ref-type="fig"}a--c). The CD15^+^ cells were also positive for both CD11b and CD33 (Fig. [1](#cas12866-fig-0001){ref-type="fig"}c). However, there was no correlation between the percentage of G‐MDSC and M‐MDSC (Fig. [1](#cas12866-fig-0001){ref-type="fig"}d).

![Identification of monocytic‐myeloid‐derived suppressor cells (M‐MDSC) in peripheral blood cells. M‐MDSC were defined as the HLA‐DR^−/low^ CD14^+^ cell population. Granulocytic‐myeloid‐derived suppressor cells (G‐MDSC) were defined as the HLA‐DR^−^ Lin^−^ CD14^−^ CD15^+^ cell population. (a--c) Representative staining and gating of M‐MDSC and G‐MDSC in peripheral blood cells (PBC) from a healthy donor, M‐MDSC from a patient with head and neck squamous cell carcinoma (HNSCC) and G‐MDSC from a patient with HNSCC, respectively. The CD15^+^ fraction of G‐MDSC stained positive for CD11b^+^ and CD33^+^. (d) No significant correlation was seen between the percentages of M‐MDSC and G‐MDSC in HNSCC patients.](CAS-107-207-g001){#cas12866-fig-0001}

Clinical features of monocytic myeloid‐derived suppressor cells in patients with head and neck tumors {#cas12866-sec-0012}
-----------------------------------------------------------------------------------------------------

The percentage of CD14^+^ HLA‐DR^−/low^ M‐MDSC was significantly elevated in patients with HNSCC (Fig. [2](#cas12866-fig-0002){ref-type="fig"}a). There was no significant correlation between the percentages of M‐MDSC and lymphocytes in the white blood cell fraction or CD3^+^, CD19^+^, CD56^+^ and Vα24^+^ Vβ11^+^ cells in the PBC of HNSCC patients (Fig. [2](#cas12866-fig-0002){ref-type="fig"}b--f).

![Percentage of monocytic‐myeloid‐derived suppressor cells (M‐MDSC) in peripheral blood cells and the correlation with the percentage of peripheral lymphocytes. (a) The percentage of CD14^+^ HLA‐DR^−/low^ M‐MDSC from healthy donors and patients with pleomorphic adenoma, thyroid papillary carcinoma and head and neck squamous cell carcinoma (HNSCC). (b) The correlation between the percentage of M‐MDSC and the percentage of circulating lymphocytes in HNSCC patients. (c--f) The correlation between the percentage of M‐MDSC and lymphocyte subsets in HNSCC patients. \*\**P* \< 0.01.](CAS-107-207-g002){#cas12866-fig-0002}

Clinical features of granulocytic‐myeloid‐derived suppressor cells in patients with head and neck tumor {#cas12866-sec-0013}
-------------------------------------------------------------------------------------------------------

The percentage of HLA‐DR^−^ Lin^−^ CD15^+^ G‐MDSC was significantly increased in patients with HNSCC compared with pleomorphic adenoma patients or healthy donors (Fig. [3](#cas12866-fig-0003){ref-type="fig"}a). No correlation was detected between the proportion of G‐MDSC and the lymphocyte subsets, including CD19^+^, CD56^+^ and Vα24^+^ Vβ11^+^ cells (Fig. [3](#cas12866-fig-0003){ref-type="fig"}b,d--f). However, a significant inverse correlation was detected between the ratio of HLA‐DR^−^ Lin^−^ CD14^−^ CD15^+^ G‐MDSC and CD3^+^ cells (*P* \< 0.01; Fig. [3](#cas12866-fig-0003){ref-type="fig"}c). To examine the correlation between MDSC and the clinical course, the ratio of G‐MDSC in five HNSCC patients with a high percentage (\>1%) of G‐MDSC before treatment were counted again after 2 months of treatment. All five patients had a complete response after treatment, with significant decreases in the frequencies of circulating G‐MDSC detected following standard treatments (one patient treated with surgery alone, 2 with surgery and chemoradiotherapy and 2 with chemoradiotherapy alone; Fig. [3](#cas12866-fig-0003){ref-type="fig"}g). The ratio of CD3^+^ cells and Vα24^+^ Vβ11^+^ cells in the five patients were not significantly changed after treatment (data not shown).

![Percentage of granulocytic‐myeloid‐derived suppressor cells (G‐MDSC) in peripheral blood cells and the correlation with the percentage of peripheral lymphocytes. (a) The percentage of HLA‐DR^−^ Lin^−^ CD15^+^ G‐MDSC from healthy donors and patients with pleomorphic adenoma, thyroid papillary carcinoma and head and neck squamous cell carcinoma (HNSCC). (b--f) The correlation between the percentage of G‐MDSC and the percentage of circulating lymphocytes subsets in HNSCC patients. (g) The percentage of HLA‐DR^−^ Lin^−^ CD14^−^ CD15^+^ G‐MDSC at pre‐standard and post‐standard therapy in HNSCC patients. \**P* \< 0.05, \*\**P* \< 0.01.](CAS-107-207-g003){#cas12866-fig-0003}

Association of myeloid‐derived suppressor cell subsets with tumor differentiation, clinical stage and prognosis in head and neck squamous cell carcinoma patients {#cas12866-sec-0014}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------

The association of tumor differentiation and clinical stage of HNSCC with the ratio of G‐MDSC, M‐MDSC and CD3^+^ cells in PBC before treatment were analyzed in a total of 32 patients with HNSCC. There were no significant differences in the percentage of G‐MDSC, M‐MDSC and CD3^+^ cell in the pathological differentiation (Table [2](#cas12866-tbl-0002){ref-type="table-wrap"}). The percentage of G‐MDSC was significantly higher in patients with advanced stage III/IV compared with those with stage I/II (Fig. [4](#cas12866-fig-0004){ref-type="fig"}b), but not in M‐MDSC (Fig. [4](#cas12866-fig-0004){ref-type="fig"}a). There were no significant differences in CD3^+^ cells between the clinical stages (Fig. [4](#cas12866-fig-0004){ref-type="fig"}c). The percentage of iNKT cells in HNSCC patients was not decreased compared with healthy donors (Fig. [4](#cas12866-fig-0004){ref-type="fig"}d). The overall survival rate in the HNSCC patients with increased M‐MDSC (\>3%) were not significantly different compared with those of patients with normal numbers of M‐MDSC in all stages (Fig. [4](#cas12866-fig-0004){ref-type="fig"}e), stage III/IV (Fig. [4](#cas12866-fig-0004){ref-type="fig"}f) or stage IV (data not shown). However, the overall survival rate in HNSCC patients with increased G‐MDSC (\>1%) was significantly lower compared with survival of patients with normal levels of G‐MDSC in all stages (Fig. [4](#cas12866-fig-0004){ref-type="fig"}g), stage III/IV (Fig. [4](#cas12866-fig-0004){ref-type="fig"}h) and stage IV (data not shown).

###### 

Categorical measurement in patients with head and neck squamous cell carcinoma (HNSCC)

  Category                                           G‐MDSC              M‐MDSC              CD3^+^ cells
  -------------------------------------------------- ------------------- ------------------- -------------------
  *Healthy control*,*n =* 18                         0.35 (0.05--0.92)   0.79 (0.25--1.27)   64.6 (49.7--81.5)
  *HNSCC*,*n =* 32                                   1.69 (0.06--6.78)   4.48 (0.38--25.8)   59.4 (30.2--80.6)
  *P*‐value[†](#cas12866-note-0003){ref-type="fn"}   \<0.01              \<0.01              0.36
  Well‐differentiated, *n =* 13                      1.01 (0.11--3.38)   4.66 (0.38--25.8)   63.2 (38.7--80.6)
  Moderately diff., *n =* 12                         2.34 (0.13--6.78)   3.11 (0.39--11.5)   56.5 (30.2--80.1)
  Poorly diff., *n =* 7                              1.83 (0.06--6.34)   6.49 (1.99--16.8)   57.3 (38.2--74.5)
  *P*‐value[‡](#cas12866-note-0003){ref-type="fn"}   0.21                0.43                0.49
  Stage I, II, *n =* 5                               0.46 (0.11--1.47)   1.74 (0.38--3.14)   55.9 (38.7--72.9)
  Stage III, IV, *n =* 27                            1.92 (0.06--6.78)   4.98 (0.39--25.8)   60.1 (30.2--80.6)
  *P*‐value[†](#cas12866-note-0003){ref-type="fn"}   \<0.05              0.20                0.51

Data shown average % (range), ^†^Unpaired *t*‐test, ^‡^ [anova]{.smallcaps}. G‐MDSC, granulocytic‐myeloid‐derived suppressor cells; M‐MDSC, monocytic‐myeloid‐derived suppressor cells.
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![Association of myeloid‐derived suppressor cells subsets with clinical stage and prognosis in head and neck squamous cell carcinoma (HNSCC) patients. (a--d) The percentages of monocytic‐myeloid‐derived suppressor cells (M‐MDSC), granulocytic‐myeloid‐derived suppressor cells (G‐MDSC), CD3^+^ cells and invariant NKT (iNKT) cells from healthy donors and patients with HNSCC with stage I/II and stage III/IV. The rate of survival between high (\>3%) and low (\<3%) percentages of M‐MDSC in all stages (e) and stage III/IV (f). The rate of survival between high (\>1%) and low (\<1%) percentages of G‐MDSC in all stages (g) and stage III/IV (h). \**P* \< 0.05. \*\**P* \< 0.01.](CAS-107-207-g004){#cas12866-fig-0004}

Suppressive effect of circulating myeloid‐derived suppressor cells on T cells {#cas12866-sec-0015}
-----------------------------------------------------------------------------

T cell proliferation in the presence or absence of CD15^+^ cells stimulated with anti‐CD3 and anti‐CD28 antibodies for 48 h was examined. In a representative HNSCC patient, CD15^+^ cells were positive in 16.7% of the HLA‐DR^−^ Lin^−^ fraction of PBC and 0.1% positive after depletion (Fig. [5](#cas12866-fig-0005){ref-type="fig"}a). Proliferation of both CD4^+^ and CD8^+^ T cells was enhanced by the depletion of CD15^+^ cells (Fig. [5](#cas12866-fig-0005){ref-type="fig"}b). In addition, T cell proliferation and viability following the depletion or addition of CD15^+^ cells was compared. In an HNSCC patient, CD15^+^ cells were positive in 2.05% of the HLA‐DR^−^ Lin^−^ fraction of PBC and 0.05% positive after depletion. The cell numbers of CD3^+^, CD4^+^ and CD8^+^ cells in CD15^+^ cell‐added PBC stimulated with anti‐CD3/28 antibody were significantly lower compared with those without CD15^+^ cells after 72 h (Fig. [5](#cas12866-fig-0005){ref-type="fig"}c--e). Proliferation of both CD4^+^ and CD8^+^ T cells was suppressed by the addition of CD15^+^ cells (Fig. [5](#cas12866-fig-0005){ref-type="fig"}g). Levels of IL‐10 were higher in the culture supernatant at 24 h in CD15^+^ cell‐added PBC (Fig. [5](#cas12866-fig-0005){ref-type="fig"}h). The levels of IL‐4 and granulocyte macrophage colony‐stimulating factor (GM‐CSF) were not significantly different in the presence or absence of CD15^+^ cells (data not shown). Catalase was added into culture of T cells, and the proliferation and viability of T cells were largely recovered its addition in the presence of CD15^+^ G‐MDSC (Fig. [5](#cas12866-fig-0005){ref-type="fig"}i,j). All experiments were repeated at least twice with similar results.

![Granulocytic‐myeloid‐derived suppressor cells (G‐MDSC) suppress autologous T cell proliferation. (a) The percentage of CD15^+^ cells in HLA‐DR^−^ Lin^−^ fraction of whole peripheral blood cells (PBC) from a head and neck squamous cell carcinoma (HNSCC) patient before (left) and after (right) depletion by CD15 magnetic beads. (b) PBC depleted or not depleted of CD15^+^ cells were stained with carboxy‐fluorescein diacetate succinimidyl ester (CFSE) and stimulated with anti‐CD3/anti‐CD28 antibodies for 48 h. The difference in CD4^+^ and CD8^+^ T cell proliferation was assessed by CFSE dilution. PBC depleted of or with added CD15^+^ cells were stained with CellTrace Violet and stimulated with anti‐CD3/anti‐CD28 antibodies for 72 h. (c--e) The differences in CD3^+^, CD4^+^ and CD8^+^ cell number were counted, and (g) CD4^+^ and CD8^+^ cell proliferation was assessed by CTV dilution. (h) Levels of interleukin (IL)‐10 were measured in supernatants of T cell cultures at 24 h. (f) PBC depleted of or with added CD15^+^ cells were cultured for 5 days stimulated with αGalCer, and invariant NKT (iNKT) cell number was counted. (i, j) PBC depleted or not depleted CD15^+^ cells were stimulated with anti‐CD3/anti‐CD28 antibodies with or without catalase (Cat) for 72 h. The difference in CD3^+^ cell number was counted and cell death was assessed by the percentage of PI^+^ cells in CD3^+^cells. \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001.](CAS-107-207-g005){#cas12866-fig-0005}

The activation of invariant NKT cells stimulated by αGalCer is not affected by granulocytic‐myeloid‐derived suppressor cells {#cas12866-sec-0016}
----------------------------------------------------------------------------------------------------------------------------

We evaluated the proliferation and viability of iNKT cells and IFN‐γ production following stimulation with αGalCer in the presence or absence of CD15^+^ cells. In a representative HNSCC patient, the CD15^+^ cells comprised 15.8% of the HLA‐DR^−^ Lin^−^ fraction in PBC, and after CD15^+^ cell depletion, only 0.01% were positive (Fig. [6](#cas12866-fig-0006){ref-type="fig"}a). There was no significant difference in the cell number (Fig. [6](#cas12866-fig-0006){ref-type="fig"}b), the ratio in PBC (Fig. [6](#cas12866-fig-0006){ref-type="fig"}c) and the cell death in iNKT cells (Fig. [6](#cas12866-fig-0006){ref-type="fig"}d,e) between CD15^+^ cell replete cultures and CD15^+^ cell‐depleted cultures after 5 days. There was no significant difference in the IFN‐γ production of iNKT cells between non‐depleted and CD15^+^ cell‐depleted cultures after 5 days (Fig. [6](#cas12866-fig-0006){ref-type="fig"}f). Similarly, 5 days after stimulation with αGalCer, there was no difference in iNKT cell number between CD15^+^ cell‐depleted and CD15^+^ cell‐added PBC (Fig. [5](#cas12866-fig-0005){ref-type="fig"}f). These results were repeated in three samples.

![Invariant NKT (iNKT) cells are resistant to granulocytic‐myeloid‐derived suppressor cells (G‐MDSC). (a) The percentage of CD15^+^ cells in the HLA‐DR^−^ Lin^−^ fraction of whole peripheral blood cells (PBC) from a head and neck squamous cell carcinoma (HNSCC) patient before (left) and after (right) depletion by CD15 magnetic beads. PBC with and without CD15^+^ cells were cultured for 5 days, stimulated with αGalCer. (b--e) The cell numbers were counted, and the staining profile, percentage of cell death and apoptosis of iNKT cells were assessed by flow cytometry. (f) IFN‐γ produced by iNKT cells was assessed by ELISPOT after 5 days. NS, not significant.](CAS-107-207-g006){#cas12866-fig-0006}

Discussion {#cas12866-sec-0017}
==========

In this study, we investigated the human MDSC subsets in patients with head and neck tumors, including benign pleomorphic adenoma, thyroid papillary carcinoma and squamous cell carcinoma, and healthy donors. We observed a significant increase in the percentage of both CD14^+^ HLA‐DR^−/low^ M‐MDSC and HLA‐DR^−^ Lin^−^ CD15^+^ G‐MDSC in PBC from HNSCC patients, but not in patients with other head and neck tumors. However, there was no correlation between the percentages of G‐MDSC and M‐MDSC, suggesting that they independently accumulated in the peripheral blood of HNSCC patients. In HNSCC patients, the percentage of circulating G‐MDSC had an inverse correlation with the ratio of T cells in PBC, suggesting that G‐MDSC preferentially suppress T cell proliferation or viability. Therefore, we investigated the suppressive capabilities of G‐MDSC on T cells. Depletion of CD15^+^ G‐MDSC in PBC from HNSCC patients enhanced the T cell proliferation and decreased T cell death, and, inversely, addition of CD15^+^ G‐MDSC into PBC suppressed the T cell proliferation. However, the H~2~O~2~ scavenger catalase reversed the suppressive activity of CD15^+^ G‐MDSC against T cells. These results indicated that circulating G‐MDSC have potent suppressive activity toward both CD4^+^ and CD8^+^ T cells, and H~2~O~2~ was one of the main suppressive factors produced by G‐MDSC. In addition, the level of IL‐10 was increased in supernatant of T cell culture in CD15^+^ cell‐added PBC, suggesting that G‐MDSC enhance IL‐10 production by T cells and could indirectly suppress the activation of T cells. MDSC reportedly have the potential to suppress the T cell‐mediated immune response through their production of arginase‐1 (Arg‐1), NO,[26](#cas12866-bib-0026){ref-type="ref"}, [29](#cas12866-bib-0029){ref-type="ref"}, [30](#cas12866-bib-0030){ref-type="ref"} ROS[31](#cas12866-bib-0031){ref-type="ref"}, [32](#cas12866-bib-0032){ref-type="ref"} and immunosuppressive cytokines, such as TGF‐β, IL‐4, IL‐6 and IL‐10, in experimental animal models.[9](#cas12866-bib-0009){ref-type="ref"} In mice, M‐MDSC express high levels of NO, while G‐MDSC express high levels of ROS, with their suppressive function dependent on Arg‐1 and the production of ROS.[33](#cas12866-bib-0033){ref-type="ref"}

In this study, we found that the percentage of G‐MDSC in PBC in patients with HNSCC post‐standard therapy was significantly decreased compared with G‐MDSC pre‐standard therapy. This result suggests that the eradication of tumors decreased the induction of G‐MDSC by HNSCC. However, the percentages of CD3^+^ cells were not increased after treatment, suggesting that radiation and chemotherapy might effect and prolong the suppression of T cells. In addition, it was demonstrated that G‐MDSC were significantly associated with the poor prognosis in HNSCC patients in this study, indicating that G‐MDSC is a clinically significant factor.

The development of new treatment strategies, such as cancer immunotherapy, is expected to improve both the prognosis and quality of life of HNSCC patients. Recently, our group has shown efficacy of an iNKT cell‐based cancer immunotherapy for HNSCC patients.[22](#cas12866-bib-0022){ref-type="ref"}, [23](#cas12866-bib-0023){ref-type="ref"}, [24](#cas12866-bib-0024){ref-type="ref"}, [25](#cas12866-bib-0025){ref-type="ref"} However, the effects of MDSC on iNKT cells have been unclear. Thus, in this study, the effect of circulating MDSC on iNKT cells was investigated. No correlation was found between the percentage of M‐MDSC or G‐MDSC and iNKT cells in PBC. Next, we evaluated the iNKT cell proliferation, viability and IFN‐γ production in the presence or absence of CD15^+^ G‐MDSC. However, upon stimulation with αGalCer, the iNKT cells in PBC expanded equally, and there was no difference in IFN‐γ production, regardless of the G‐MDSC. In mice, reportedly, iNKT cells could convert CD11b^+^ Gr1^+^ MDSC into stimulatory APC, or suppress CD11b^+^ Ly‐6G^+^ Ly‐6C^+^ MDSC in a CD1d‐dependent manner.[34](#cas12866-bib-0034){ref-type="ref"}, [35](#cas12866-bib-0035){ref-type="ref"} The association of iNKT cells with MDSC has been poorly understood in humans, including cancer patients. From our results, it is suggested that G‐MDSC from HNSCC patients produce H~2~O~2~, and while T cells are sensitive to H~2~O~2~, iNKT cells are resistant. From these results, it could be expected that cancer immunotherapy to enhance the antitumor activity of iNKT cells using αGalCer might not be inhibited, and is, therefore, more likely to be effective in HNSCC patients, even in the presence of G‐MDSC. However, because the antitumor activity of iNKT cells mediates T cell activation,[36](#cas12866-bib-0036){ref-type="ref"} it is expected that targeted therapy to reduce MDSC will also enhance the therapeutic efficacy of iNKT cell‐based immunotherapy.

In conclusion, we found a significant increase in the circulating M‐MDSC and G‐MDSC, and increased G‐MDSC was associated with poor prognosis in HNSCC patients. The percentage of G‐MDSC in PBC showed an inverse correlation with the percentage of T cells, and T cell proliferation and viability were suppressed by G‐MDSC. The suppression was reversed by catalase, suggesting that G‐MDSC constitutively suppress the proliferation and viability of peripheral T cells mediated by H~2~O~2~. Meanwhile, iNKT cells showed resistance to the suppressive activity of G‐MDSC, suggesting that iNKT cells had a higher antioxidative capacity than T cells. Cancer immunotherapy to enhance the antitumor activity of iNKT cells by stimulation with αGalCer is likely to remain effective even in the presence of G‐MDSC.
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